Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in adolescent plaque psoriasis
NCT04305327Phase 3Terminated
- Sponsor
- LEO Pharma
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of brodalumab in plaque psoriasis, sponsored by LEO Pharma. Started Dec 2022; status: terminated.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04305327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305327.